Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) yesterday and set a price target ...

AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...

The firm's stance comes in the wake of recent clinical trial outcomes for Axsome's drug Auvelity, which is under consideration for the treatment of Alzheimer's disease agitation (ADA). The trials ...

The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.

TD Cowen, a well-established research firm, increased its price target on Axsome Therapeutics (NASDAQ:AXSM) shares, raising the figure to $155 from the previous target of $125. The firm reaffirmed its ...

Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi ...

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...

Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi preliminary 4Q and full year 2024 net product revenue of $25.7 million and $93 ...